Format

Send to

Choose Destination
Brain. 2016 Dec;139(Pt 12):3092-3108. Epub 2016 Oct 25.

Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.

Author information

1
1 Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
2
2 Department of Genetics, Washington University School of Medicine, Saint Louis, MO, USA.
3
2 Department of Genetics, Washington University School of Medicine, Saint Louis, MO, USA diantonio@wustl.edu jmilbrandt@wustl.edu.
4
3 Hope Center for Neurological Diseases, Washington University School of Medicine, Saint Louis, MO, USA.
5
3 Hope Center for Neurological Diseases, Washington University School of Medicine, Saint Louis, MO, USA diantonio@wustl.edu jmilbrandt@wustl.edu.
6
4 Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO, USA.

Abstract

Peripheral polyneuropathy is a common and dose-limiting side effect of many important chemotherapeutic agents. Most such neuropathies are characterized by early axonal degeneration, yet therapies that inhibit this axonal destruction process do not currently exist. Recently, we and others discovered that genetic deletion of SARM1 (sterile alpha and TIR motif containing protein 1) dramatically protects axons from degeneration after axotomy in mice. This finding fuels hope that inhibition of SARM1 or its downstream components can be used therapeutically in patients threatened by axonal loss. However, axon loss in most neuropathies, including chemotherapy-induced peripheral neuropathy, is the result of subacute/chronic processes that may be regulated differently than the acute, one time insult of axotomy. Here we evaluate if genetic deletion of SARM1 decreases axonal degeneration in a mouse model of neuropathy induced by the chemotherapeutic agent vincristine. In wild-type mice, 4 weeks of twice-weekly intraperitoneal injections of 1.5 mg/kg vincristine cause pronounced mechanical and heat hyperalgesia, a significant decrease in tail compound nerve action potential amplitude, loss of intraepidermal nerve fibres and significant degeneration of myelinated axons in both the distal sural nerve and nerves of the toe. Neither the proximal sural nerve nor the motor tibial nerve exhibit axon loss. These findings are consistent with the development of a distal, sensory predominant axonal polyneuropathy that mimics vincristine-induced peripheral polyneuropathy in humans. Using the same regimen of vincristine treatment in SARM1 knockout mice, the development of mechanical and heat hyperalgesia is blocked and the loss in tail compound nerve action potential amplitude is prevented. Moreover, SARM1 knockout mice do not lose unmyelinated fibres in the skin or myelinated axons in the sural nerve and toe after vincristine. Hence, genetic deletion of SARM1 blocks the development of vincristine-induced peripheral polyneuropathy in mice. Our results reveal that subacute/chronic axon loss induced by vincristine occurs via a SARM1 mediated axonal destruction pathway, and that blocking this pathway prevents the development of vincristine-induced peripheral polyneuropathy. These findings, in conjunction with previous studies with axotomy and traumatic brain injury, establish SARM1 as the central determinant of a fundamental axonal degeneration pathway that is activated by diverse insults. We suggest that targeting SARM1 or its downstream effectors may be a viable therapeutic option to prevent vincristine-induced peripheral polyneuropathy and possibly other peripheral polyneuropathies.

KEYWORDS:

CIPN; SARM1; axonal degeneration; chemotherapy-induced peripheral neuropathy; vincristine

PMID:
27797810
PMCID:
PMC5840884
DOI:
10.1093/brain/aww251
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center